Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6383MR)

This product GTTS-WQ6383MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6383MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8865MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ9854MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ7824MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ13524MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ11625MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ7335MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ3790MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ10553MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW